Skip Nav Destination
Issues
1 November 2006
-
Cover Image
Cover Image
Array-based CGH identifies multiple genomic alterations in MSI-H and MSS colorectal tumors. A small, previously uncharacterized deletion at 16p13.2 was found in 35% of MSI-H and 21% of MSS tumors. Figure shows homozygous deletion of this region by dual-color FISH. Nuclei (blue) show two signals for 16 centromere (green) and the absence of signals for a BAC at 16p13.2 (labeled in red). FISH to an adjacent BAC control showed two red signals. For further details, please see Trautmann et al. on page 6379 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Human Cancer Biology
Activation of Hypoxia-Inducible Factor-1α Is Necessary for Lysophosphatidic Acid–Induced Vascular Endothelial Growth Factor Expression
Jangsoon Lee; Soon Young Park; Eun Kyung Lee; Chang Gyo Park; Hyun Cheol Chung; Sun Young Rha; Yong Kee Kim; Gyu-Un Bae; Bum Kyeong Kim; Jeung-Whan Han; Hoi Young Lee
Distribution of GPR30, a Seven Membrane–Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression
Edward J. Filardo; Carl T. Graeber; Jeffrey A. Quinn; Murray B. Resnick; Dilip Giri; Ronald A. DeLellis; Margaret M. Steinhoff; Edmond Sabo
Imaging, Diagnosis, Prognosis
CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
Donal J. Brennan; Karin Jirstrom; Åsa Kronblad; Robert C. Millikan; Goran Landberg; Michael J. Duffy; Lisa Rydén; William M. Gallagher; Sallyann L. O'Brien
Prognostic Value of Apoptosis in Rectal Cancer Patients of the Dutch Total Mesorectal Excision Trial: Radiotherapy Is Redundant in Intrinsically High-Apoptotic Tumors
Elza C. de Bruin; Cornelis J.H. van de Velde; Simone van de Pas; Iris D. Nagtegaal; J. Han J.M. van Krieken; Marleen J.E.M. Gosens; Lucy T.C. Peltenburg; Jan Paul Medema; Corrie A.M. Marijnen
Peroxisome Proliferator-Activated Receptor γ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times
Glen Kristiansen; Juliane Jacob; Ann-Christin Buckendahl; Robert Grützmann; Ingo Alldinger; Bence Sipos; Günter Klöppel; Marcus Bahra; Jan M. Langrehr; Peter Neuhaus; Manfred Dietel; Christian Pilarsky
Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy
Robert K. Nam; William W. Zhang; Laurence H. Klotz; John Trachtenberg; Michael A.S. Jewett; Joan Sweet; Ants Toi; Seamus Teahan; Vasundara Venkateswaran; Linda Sugar; Andrew Loblaw; Kathy Siminovitch; Steven A. Narod
Cancer Therapy: Clinical
Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up
Ercole Brusamolino; Ambrogia Baio; Ester Orlandi; Luca Arcaini; Francesco Passamonti; Vassiliki Griva; William Casagrande; Cristiana Pascutto; Pietro Franchini; Mario Lazzarino
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Marissa N. Balak; Yixuan Gong; Gregory J. Riely; Romel Somwar; Allan R. Li; Maureen F. Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G. Kris; Marc Ladanyi; Vincent A. Miller; William Pao
A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug
Astrid Mayer; Roslyn J. Francis; Surinder K. Sharma; Berend Tolner; Caroline J. Springer; Jan Martin; Geoff M. Boxer; James Bell; Alan J. Green; John A. Hartley; Clare Cruickshank; Julie Wren; Kerry A. Chester; Richard H.J. Begent
Cancer Therapy: Preclinical
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib
Paul La Rosée; Taiping Jia; Shadmer Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W. Singer; Junia V. Melo; Brian J. Druker; Michael W. Deininger
Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines
Ana I. Robles; Mollie H. Wright; Bheru Gandhi; Steven S. Feis; Christin L. Hanigan; Adrian Wiestner; Lyuba Varticovski
Hedgehog: an Attribute to Tumor Regrowth after Chemoradiotherapy and a Target to Improve Radiation Response
Jennifer Sims-Mourtada; Julie G. Izzo; Smith Apisarnthanarax; Tsung-Teh Wu; Usha Malhotra; Rajyalashmi Luthra; Zhongxing Liao; Ritsuko Komaki; Albert van der Kogel; Jaffer Ajani; K.S. Clifford Chao
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
Yan Wu; Zhaojing Zhong; James Huber; Rajiv Bassi; Bridget Finnerty; Erik Corcoran; Huiling Li; Elizabeth Navarro; Paul Balderes; Xenia Jimenez; Henry Koo; Venkata R.M. Mangalampalli; Dale L. Ludwig; James R. Tonra; Daniel J. Hicklin
Cancer Susceptibility and Prevention
Advertisement